Lessons learnt from gefitinib and erlotinib: Key insights into small-molecule EGFR-targeted kinase inhibitors in non-small cell lung cancer
Eckart Laack, Guido Sauter, Carsten Bokemeyer
20100801
2010 Sept 1
Lung Cancer
Lessons learnt from gefitinib and erlotinib: Key insights into small-molecule EGFR-targeted kinase inhibitors in non-small cell lung cancer
Lung Cancer. 2010 Sept;69(3):259-264, Eckart Laack, Guido Sauter, Carsten Bokemeyer
Abstract
Abstract
Improving treatment options and patient outcomes for those with non-small cell lung cancer (NSCLC) represents a significant worldwide challenge. Although traditional treatment strategies are widely accepted and initially successful, many tumors still fail to respond to available drugs. Therapeutic options for patients with NSCLC are therefore moving towards more individual and personalized treatment strategies. The first-generation tyrosine kinase inhibitors (TKIs), designed to target specific molecular...
